An interventional study of Serratus anterior plane block and Fentanyl (IV) in Breast Neoplasms and Pain, Postoperative, sponsored by Sanliurfa Education and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Sanliurfa Education and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 179th largest by enrollment of the 321 interventional ones that give a count, is one of 46 that started in 2023, is one of 184 with no phase, and was the 400th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 46 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 72 across 10,914 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 321 interventional studies, 80 across the 79 observational. Of the 247 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 400 have an industry lead sponsor. The 10 most frequent:
Sanliurfa Education and Research Hospital is the lead sponsor of 25 studies on the registry; 10 are open to participants now.
Sanliurfa Education and Research Hospital has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, open-label trial compared an ultrasound-guided serratus anterior plane (SAP) block performed at the third rib level at the end of surgery plus fentanyl patient-controlled analgesia (PCA) with PCA alone in women undergoing breast cancer surgery with an axillary procedure. The primary outcome was cumulative PCA fentanyl consumption in the first 12 postoperative hours.
Women aged 18 to 65 years with ASA physical status I-III who were scheduled for elective unilateral breast cancer surgery with sentinel lymph node biopsy or axillary lymph node dissection were randomized by the sealed-envelope method to two groups. All patients received standardized general anesthesia. In Group S, an ultrasound-guided SAP block was performed after completion of surgery and before emergence, at the level where the third rib crosses the midaxillary line, with 30 mL of 0.25% bupivacaine injected into the fascial plane deep to the serratus anterior muscle. Group H received no block. Both groups received intravenous fentanyl PCA for 24 hours (20 µg bolus, 15-minute lockout, no basal infusion). No sham block was performed, and the study was open-label. Fentanyl consumption, PCA demands, and pain scores were recorded at 0, 2, 6, 12, and 24 hours after surgery. Time to first mobilization, pain during arm abduction at 24 hours, and postoperative nausea and vomiting were also recorded. This study was registered retrospectively, after completion of enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ultrasound-guided serratus anterior plane block at the third rib level after surgery, plus intravenous fentanyl patient-controlled analgesia for 24 hours.
Procedure: Serratus anterior plane block · Drug: Fentanyl (IV)
Intravenous fentanyl patient-controlled analgesia for 24 hours, without a block.
Drug: Fentanyl (IV)
Ultrasound-guided block at the third rib level on the midaxillary line with 30 mL of 0.25% bupivacaine, performed after surgery and before emergence from general anesthesia.
Intravenous fentanyl 10 µg/mL by patient-controlled analgesia pump for 24 hours; 20 µg bolus, 15-minute lockout, no basal infusion.
Cumulative fentanyl consumption at 12 hours
Total fentanyl delivered by the PCA pump (µg)
Time frame: First 12 hours after surgery
Cumulative fentanyl consumption at other time points
otal fentanyl delivered by the PCA pump (µg)
Time frame: 0, 2, 6, and 24 hours after surgery
Postoperative pain score
Numeric Rating Scale, 0 (no pain) to 10 (worst pain); higher scores indicate worse pain
Time frame: 0, 2, 6, 12, and 24 hours after surgery
Number of PCA demands
Cumulative number of PCA button presses
Time frame: 12 and 24 hours after surgery
Time to first mobilization
Hours until the patient gets out of bed and walks 5 to 10 meters
Time frame: Up to 24 hours after surgery
Pain score during arm abduction
Numeric Rating Scale (0 to 10) during approximately 45° abduction of the ipsilateral arm; higher scores indicate worse pain
Time frame: 24 hours after surgery
Postoperative nausea and vomiting
Number of patients with nausea and/or vomiting
Time frame: Up to 24 hours after surgery
Plan to share: Yes
Supporting information: Study protocol
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Feb 2024, 4 months.
Of 2,669 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 4 months is below that.
Counting every sponsor, half of 2,779 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanliurfa Education and Research Hospital